Teva Pharmaceutical has announced the launch of RAJANITM (drospirenone, ethinyl estradiol and levomefolate calcium tablets, 3 mg/0.02 mg/0.451 mg and levomefolate calcium tablets, 0.451 mg) in the United States. RAJANITM, the generic equivalent of Beyaz®1, is an oral contraceptive, available in a 28-day blister pack dispenser, for use by women to:
- prevent pregnancy;
- treat symptoms of premenstrual dysphoric disorder (PMDD) in women choosing to use an oral contraceptive for contraception;
- treat moderate acne for women at least 14 years old if the patient desires an oral contraceptive for birth control; and
- raise folate levels in women who choose to use an oral contraceptive for contraception.
Beyaz® had annual sales of approximately $133 million in the U.S., according to IMS data as of July 2016.